These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27671498)

  • 41. Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
    Bellale E; Naik M; V B V; Ambady A; Narayan A; Ravishankar S; Ramachandran V; Kaur P; McLaughlin R; Whiteaker J; Morayya S; Guptha S; Sharma S; Raichurkar A; Awasthy D; Achar V; Vachaspati P; Bandodkar B; Panda M; Chatterji M
    J Med Chem; 2014 Aug; 57(15):6572-82. PubMed ID: 24967731
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antimycobacterial activities of novel fluoroquinolones.
    Senthilkumar P; Dinakaran M; Yogeeswari P; China A; Nagaraja V; Sriram D
    Biomed Pharmacother; 2009 Jan; 63(1):27-35. PubMed ID: 18031974
    [TBL] [Abstract][Full Text] [Related]  

  • 43. L-proline-catalysed facile green protocol for the synthesis and antimycobacterial evaluation of [1,4]-thiazines.
    Indumathi S; Perumal S; Banerjee D; Yogeeswari P; Sriram D
    Eur J Med Chem; 2009 Dec; 44(12):4978-84. PubMed ID: 19781824
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents.
    Ramesh R; Shingare RD; Kumar V; Anand A; B S; Veeraraghavan S; Viswanadha S; Ummanni R; Gokhale R; Srinivasa Reddy D
    Eur J Med Chem; 2016 Oct; 122():723-730. PubMed ID: 27476117
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
    Singh S; Roy KK; Khan SR; Kashyap VK; Sharma A; Jaiswal S; Sharma SK; Krishnan MY; Chaturvedi V; Lal J; Sinha S; Dasgupta A; Srivastava R; Saxena AK
    Bioorg Med Chem; 2015 Feb; 23(4):742-52. PubMed ID: 25614114
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs.
    Blanco D; Perez-Herran E; Cacho M; Ballell L; Castro J; González Del Río R; Lavandera JL; Remuiñán MJ; Richards C; Rullas J; Vázquez-Muñiz MJ; Woldu E; Zapatero-González MC; Angulo-Barturen I; Mendoza A; Barros D
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1868-75. PubMed ID: 25583730
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2'-Oxidase.
    Oh S; Park Y; Engelhart CA; Wallach JB; Schnappinger D; Arora K; Manikkam M; Gac B; Wang H; Murgolo N; Olsen DB; Goodwin M; Sutphin M; Weiner DM; Via LE; Boshoff HIM; Barry CE
    J Med Chem; 2018 Nov; 61(22):9952-9965. PubMed ID: 30350998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207.
    Guillemont J; Meyer C; Poncelet A; Bourdrez X; Andries K
    Future Med Chem; 2011 Sep; 3(11):1345-60. PubMed ID: 21879841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and evaluation of the 2,4-diaminoquinazoline series as anti-tubercular agents.
    Odingo J; O'Malley T; Kesicki EA; Alling T; Bailey MA; Early J; Ollinger J; Dalai S; Kumar N; Singh RV; Hipskind PA; Cramer JW; Ioerger T; Sacchettini J; Vickers R; Parish T
    Bioorg Med Chem; 2014 Dec; 22(24):6965-79. PubMed ID: 25456390
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
    Onajole OK; Pieroni M; Tipparaju SK; Lun S; Stec J; Chen G; Gunosewoyo H; Guo H; Ammerman NC; Bishai WR; Kozikowski AP
    J Med Chem; 2013 May; 56(10):4093-103. PubMed ID: 23611124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of novel bis-oxazolidinone compounds as potential potent and selective antitubercular agents.
    Ang W; Ye W; Sang Z; Liu Y; Yang T; Deng Y; Luo Y; Wei Y
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1496-501. PubMed ID: 24582981
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
    Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Shortening the treatment of tuberculosis.
    Mitchison DA
    Nat Biotechnol; 2005 Feb; 23(2):187-8. PubMed ID: 15696148
    [No Abstract]   [Full Text] [Related]  

  • 54. Synthesis and structure activity relationship of imidazo[1,2-a]pyridine-8-carboxamides as a novel antimycobacterial lead series.
    Ramachandran S; Panda M; Mukherjee K; Choudhury NR; Tantry SJ; Kedari CK; Ramachandran V; Sharma S; Ramya VK; Guptha S; Sambandamurthy VK
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4996-5001. PubMed ID: 23867166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.
    Wang A; Lv K; Tao Z; Gu J; Fu L; Liu M; Wan B; Franzblau SG; Ma C; Ma X; Han B; Wang A; Xu S; Lu Y
    Eur J Med Chem; 2019 Nov; 181():111595. PubMed ID: 31408806
    [TBL] [Abstract][Full Text] [Related]  

  • 56. hERG optimizations of IMB1603, discovery of alternative benzothiazinones as new antitubercular agents.
    Lv K; Wang A; Tao Z; Fu L; Liu H; Wang B; Ma C; Wang H; Ma X; Han B; Wang A; Zhang K; Liu M; Lu Y
    Eur J Med Chem; 2019 Oct; 179():208-217. PubMed ID: 31254922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 2,3-dideoxy hex-2-enopyranosid-4-uloses as promising new anti-tubercular agents: design, synthesis, biological evaluation and SAR studies.
    Saquib M; Husain I; Sharma S; Yadav G; Singh VK; Sharma SK; Shah P; Siddiqi MI; Kumar B; Lal J; Jain GK; Srivastava BS; Srivastava R; Shaw AK
    Eur J Med Chem; 2011 Jun; 46(6):2217-23. PubMed ID: 21440336
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Whole cell screen based identification of spiropiperidines with potent antitubercular properties.
    Tantry SJ; Degiacomi G; Sharma S; Jena LK; Narayan A; Guptha S; Shanbhag G; Menasinakai S; Mallya M; Awasthy D; Balakrishnan G; Kaur P; Bhattacharjee D; Narayan C; Reddy J; Naveen Kumar CN; Shandil R; Boldrin F; Ventura M; Manganelli R; Hartkoorn RC; Cole ST; Panda M; Markad SD; Ramachandran V; Ghorpade SR; Dinesh N
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3234-45. PubMed ID: 26087937
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.
    Sriram D; Senthilkumar P; Dinakaran M; Yogeeswari P; China A; Nagaraja V
    J Med Chem; 2007 Nov; 50(24):6232-9. PubMed ID: 17960928
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
    Medapi B; Suryadevara P; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
    Eur J Med Chem; 2015 Oct; 103():1-16. PubMed ID: 26318054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.